AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?
Eli Lilly's metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVie's defensive dividend appeal.
Overview
The pharmaceutical market is currently defined by a race to replace aging blockbusters with next-generation therapies. Deciding whether to buy AbbVie Inc (NYSE:ABBV) or Eli Lilly and Co (NYSE:LLY) requires weighing different growth engines.
Both companies operate in the same general space but offer distinct profiles. AbbVie relies on its deep roots in immunology and neuroscience, while Eli Lilly is experiencing massive growth driven by its metabolic and obesity platform.
Details
AbbVie is a giant among pharmaceutical stocks, focusing on immunology, oncology, and neuroscience therapies. Revenue is highly concentrated, with Skyrizi and Rinvoq making up roughly 42% of sales in 2025. To diversify, the company recently announced it would acquire Apogee Therapeutics (NASDAQ:APGE) for approximately $10.9 billion.
Source
Originally published at www.fool.com.